J.D., Seattle University cum laude
Ph.D., Molecular and Cellular Biology, Baylor College of Medicine
B.A., Biology, Hope College cum laude
District of Columbia
United States Patent and Trademark Office
Dr. Nannenga-Combs is a director in the Biotechnology/Chemical Group. She counsels a diverse group of clients on the preparation, prosecution, and management of complex worldwide patent portfolios. She helps clients develop product exclusivity strategies in areas of biotechnology such as pharmaceuticals, therapeutic antibodies, vaccines, diagnostics, nucleic acid therapies, formulations, and biologics.
Dr. Nannenga-Combs is also experienced in IP due diligence investigations and freedom to operate studies, and she prepares patentability, validity, and noninfringement opinions. She is particularly skilled at identifying patent portfolio strengths and weaknesses.
Dr. Nannenga-Combs is active in the firm’s Pro Bono Practice. She works with pro bono clients to prepare and prosecute patents that can be used to help advance economic, social, and cultural rights.
Her doctorate research focused on breast cancer, specifically the characterization of PPM1D, a wild-type p53-induced phosphatase, and PPM1D's role in cell cycle and DNA damage response pathways. Dr. Nannenga-Combs also worked as a technical writer for a Washington-based biopharmaceutical company.
"Augmented Cancer Resistance and DNA Damage Response Phenotypes in PPM1D Null Mice." Bonnie Nannenga, Xiongbin Lu, Melissa Dumble, Marc Van Maanen, Thuy-Ai Nguyen, Frances Kittrell, Daniel Medina,T. Rajendra Kumar, and Lawrence A. Donehower. Molecular Carcinogenesis 2006.
"Dual roles for the phosphatase PPM1D in regulating progesterone receptor function. " Proia DA, Nannenga BW, Donehower LA, Weigel NL. J Biol Chem. March 2006.
"PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints. " Xiongbin Lu, Bonnie Nannenga, Lawrence A. Donehower. Genes & Development 2005.
"The p53-Induced Oncogenic Phosphatase Ppm1d Interacts with Uracil DNA Glycosylase and Suppresses Base Excision Repair." X. Lu, D. Bocangel, B. Nannenga, H. Yamaguchi, E. Appella and L. Donehower. Molecular Cell 2004.
"Inactivation of the Wip1 Phosphatase Inhibits Mammary Tumorigenesis through p38 MAPK-Mediated Activation on the p16Ink4a-p19Arf Tumor Suppressor Pathway." D. Bulavin, C. Phillips, B. Nannenga, O. Timofeev, L. Donehower, C. Anderson, E. Appella, A. Fornace Jr. Nature Genetics 2004.
"Mice Deficient for Wild-Type p53-Induced Phosphatase Gene (Wip1) Exhibit Defects in Reproductive Organs, Immune Function, and Cell Cycle Control." J. Choi, B. Nannenga, O. Demidov, D. Bulavin, A. Cooney, C. Brayton, Y. Zhang, I. Mbawuike, A. Bradley, E. Appella, and L. Donehower. Molecular and Cellular Biology 2002.
"Enhanced Liver Cell Mutations in Trematode-Infected Big Blue Transgenic Mice. " J. Gentile, G. Gentile, B. Nannenga, M. Johnson, H. Blankespoor, R. Montero. Mutation Research 1998.
Unsolicited e-mails and information sent to Sterne, Kessler, Goldstein & Fox P.L.L.C. will not be considered confidential or privileged, may be disclosed to others, may not receive a response, and do not create an attorney-client relationship with Sterne Kessler. If you are not already a client of Sterne Kessler, do not include any confidential information in this message.